How Secret Deals Could Keep a COVID-19 Drug Out of Reach for Millions

“These bilateral licenses … are highly restrictive in their application,” Professor Brook Baker tells the Los Angeles Times. “Gilead excluded these countries because they have commercial potential and because Gilead wants to reserve the right to prevent competition and charge higher prices.”